CAMP4 Therapeutics (NASDAQ:CAMP) Raised to Overweight at JPMorgan Chase & Co.

CAMP4 Therapeutics (NASDAQ:CAMP) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued to investors on Tuesday,Benzinga reports. The firm presently has a $9.00 price objective on the Wireless communications provider’s stock, up from their prior price objective of $5.00. JPMorgan Chase & Co.‘s target price points to a potential upside of 127.27% from the stock’s previous close.

Several other analysts also recently weighed in on CAMP. Chardan Capital set a $6.50 price target on CAMP4 Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, June 10th. Cantor Fitzgerald restated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Friday, March 6th. Weiss Ratings downgraded CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, May 21st. Rodman & Renshaw initiated coverage on CAMP4 Therapeutics in a research note on Tuesday, April 14th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Leerink Partners increased their target price on CAMP4 Therapeutics from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, April 2nd. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.36.

CAMP4 Therapeutics Stock Down 5.5%

CAMP4 Therapeutics stock opened at $3.96 on Tuesday. The company has a market capitalization of $205.64 million, a P/E ratio of -1.68 and a beta of 0.08. The stock’s 50 day moving average is $4.35 and its 200 day moving average is $4.70. CAMP4 Therapeutics has a twelve month low of $1.30 and a twelve month high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last posted its quarterly earnings results on Thursday, May 7th. The Wireless communications provider reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The company had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative return on equity of 194.74% and a negative net margin of 2,193.72%. As a group, equities analysts expect that CAMP4 Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On CAMP4 Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. bought a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at $70,000. State Street Corp lifted its holdings in shares of CAMP4 Therapeutics by 52.7% during the 4th quarter. State Street Corp now owns 39,700 shares of the Wireless communications provider’s stock valued at $243,000 after buying an additional 13,700 shares during the period. Bank of America Corp DE bought a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at $86,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of CAMP4 Therapeutics during the 4th quarter valued at $115,000.

About CAMP4 Therapeutics

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.